Literature DB >> 30961944

Clinical, serological and radiological features of a prospective cohort of Interstitial Pneumonia with Autoimmune Features (IPAF) patients.

Gianluca Sambataro1, Domenico Sambataro2, Sebastiano Emanuele Torrisi3, Ada Vancheri3, Michele Colaci4, Mauro Pavone3, Francesca Pignataro5, Nicoletta Del Papa5, Stefano Palmucci6, Carlo Vancheri3.   

Abstract

BACKGROUND: The term Interstitial Pneumonia with Autoimmune Features (IPAF) describes patients with Interstitial Lung Diseases (ILDs) and clinical or serological features of autoimmune diseases insufficient to reach a specific classification of a Connective Tissue Disease (CTD). Currently, retrospective studies on IPAF patients have proven to be heterogeneous in general characteristics, outcomes and High-Resolution Computed Tomography (HRCT) pattern. This study aims to describe for the first time the clinical, serological and radiological features of a prospective cohort of IPAF patients. This cohort is then compared to a group of patients with Idiopathic Pulmonary Fibrosis (IPF).
MATERIAL AND METHODS: From 626 consecutive ILD patients evaluated, 45 IPAF and a comparison cohort of 143 IPF patients were enrolled. All patients underwent clinical assessment with rheumatologic and respiratory evaluation, HRCT, Pulmonary Function Tests and Nailfold Videocapillaroscopy.
RESULTS: The IPAF patients had a predominance of female gender (62.12%) with a median age of 66 years. The most common findings were: Nonspecific Interstitial Pneumonia (NSIP, 68.89%), Antinuclear Antibody positivity (17.77%) and Raynaud Phenomenon (31.11%). In comparison with IPF, IPAF patients showed younger age, better performances in Pulmonary Function Tests, less necessity of O2 support and predominance of female sex and NSIP pattern. DISCUSSION: This is the first report of a prospective cohort of IPAF patients. IPAF patients seem to have a less severe lung disease than IPF. IPAF criteria probably need to be revisited and validated, but their capacity to recruit patients with incomplete forms or early onset of CTD could be useful for further research.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Classification criteria; Diagnosis; Idiopathic pulmonary fibrosis; Interstitial Pneumonia with autoimmune features; Interstitial lung disease; Undifferentiated connective tissue disease

Mesh:

Substances:

Year:  2019        PMID: 30961944     DOI: 10.1016/j.rmed.2019.03.011

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  13 in total

1.  Clinical characteristics of idiopathic interstitial pneumonias with anti-Ro52/tripartite motif-containing 21 antibodies.

Authors:  Masahiro Tahara; Noriho Sakamoto; Minoru Satoh; Hiroshi Ishimoto; Hirokazu Yura; Kei Yamasaki; Takashi Kido; Yoshihisa Fujino; Tomoko Hasegawa; Shin Tanaka; Kazuhiro Yatera; Hiroshi Mukae
Journal:  Sci Rep       Date:  2022-07-01       Impact factor: 4.996

2.  Interstitial Pneumonia with Autoimmune Features (IPAF): A Single-Centre, Prospective Study.

Authors:  Maria Karampeli; Konstantinos Thomas; Sofia Flouda; Aikaterina Chavatza; Dionisios Nikolopoulos; Antigone Pieta; Dimitrios Tseronis; Michail Aggelakos; Dimitra Kassara; Vasiliki Tzavara; Pelagia Katsimbri; Dimitrios Boumpas; Theofanis Karageorgas
Journal:  Mediterr J Rheumatol       Date:  2020-09-30

3.  Nailfold Videocapillaroscopy is a Useful Tool to Recognize Definite Forms of Systemic Sclerosis and Idiopathic Inflammatory Myositis in Interstitial Lung Disease Patients.

Authors:  Domenico Sambataro; Gianluca Sambataro; Alessandro Libra; Giovanna Vignigni; Fabio Pino; Evelina Fagone; Mary Fruciano; Elisa Gili; Francesca Pignataro; Nicoletta Del Papa; Carlo Vancheri
Journal:  Diagnostics (Basel)       Date:  2020-04-25

Review 4.  Interstitial Pneumonia With Autoimmune Features (IPAF).

Authors:  Ligia Fernandes; Mouhamad Nasser; Kais Ahmad; Vincent Cottin
Journal:  Front Med (Lausanne)       Date:  2019-09-27

5.  Interstitial pneumonia with autoimmune features: A case series and overview.

Authors:  Ana Luísa Fernandes; Jorge Ferreira; Inês Neves
Journal:  Respir Med Case Rep       Date:  2021-01-20

6.  Krebs von den Lungen-6 and surfactant protein-A in interstitial pneumonia with autoimmune features.

Authors:  Mingshan Xue; Chuanxu Cai; Yifeng Zeng; Yifan Xu; Huai Chen; Haisheng Hu; Luqian Zhou; Baoqing Sun
Journal:  Medicine (Baltimore)       Date:  2021-01-29       Impact factor: 1.817

7.  Myositis-specific Antibodies Identify A Distinct Interstitial Pneumonia with Autoimmune Features Phenotype.

Authors:  Julia Graham; Iazsmin Bauer Ventura; Chad A Newton; Cathryn Lee; Noelle Boctor; Janelle Vu Pugashetti; Claire Cutting; Elena Joerns; Habrinder Sandhu; Jonathan H Chung; Christine Kim Garcia; Michael Kadoch; Imre Noth; Ayodeji Adegunsoye; Mary E Strek; Justin M Oldham
Journal:  Eur Respir J       Date:  2020-07-16       Impact factor: 16.671

Review 8.  Recent advances in the diagnosis and management of interstitial pneumonia with autoimmune features: the perspective of rheumatologists.

Authors:  Hong Ki Min; Se-Hee Kim; Sang-Heon Lee; Hae-Rim Kim
Journal:  Korean J Intern Med       Date:  2021-02-08       Impact factor: 2.884

Review 9.  Patients with Interstitial Lung Disease Secondary to Autoimmune Diseases: How to Recognize Them?

Authors:  Domenico Sambataro; Gianluca Sambataro; Francesca Pignataro; Giovanni Zanframundo; Veronica Codullo; Evelina Fagone; Emanuele Martorana; Francesco Ferro; Martina Orlandi; Nicoletta Del Papa; Lorenzo Cavagna; Lorenzo Malatino; Michele Colaci; Carlo Vancheri
Journal:  Diagnostics (Basel)       Date:  2020-04-09

10.  Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.

Authors:  Sebastiano Emanuele Torrisi; Nicolas Kahn; Julia Wälscher; Nilab Sarmand; Markus Polke; Kehler Lars; Monika Eichinger; Claus Peter Heussel; Stefano Palmucci; Francesca Maria Sambataro; Gianluca Sambataro; Domenico Sambataro; Carlo Vancheri; Michael Kreuter
Journal:  BMC Pulm Med       Date:  2019-11-12       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.